Cognitive ImpairmentNCT06864910
Brain Functional Changes Accompany Modulatory Effects of Transcranial Direct Current Stimulation in Cognitive Impairment
An observational study of Cognitive Impairment, run by National Institute of Mental Health and Neuro Sciences, India at 2 sites in India.
Trial summary
The goal of this observational study was to examine the brain functional alterations accompanying cognitive modulatory effect of anodal transcranial Direct Current Stimulation (tDCS) in sample patients with early Alzheimer's Disease (AD), registered under Geriatric Clinic and Services at NIMHANS, and who were… Read more about this study
- Who is it for?
- Ages 55 years and older
- Conditions the study is for
- Cognitive Impairment
- What is being tested?
- anodal transcranial Direct Current Stimulation
- Type of treatment
- Medical device
- How many people
- 40 participants
- Where
- 2 sitesIndia
- Study dates
- 5 Aug 2019to 16 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 55 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All consecutive patients aged 55 and above attending the Geriatric Clinic and Services at NIMHANS with memory complaints who fulfil the following inclusion and exclusion criteria will be considered for recruitment into the study. Those diagnosed as Minimal Cognitive Impairment or Mild Alzheimer's Dementia by two consultants according to National Institute of Aging and Alzheimer's Association criteria and a Clinical Dementia Rating (CDR) of 0.5 for MCI and 1 for Mild AD would be recruited. Consenting cognitively healthy elderly subjects matched for age and gender to the above with CDR < 0.5 would be parallely recruited.
Who may be able to join
- Elderly aged 55 years or above
- Both genders
- Only right handed individuals
- Elderly with a diagnosis of Minimal Cognitive Impairment and Mild AD according to National institute of Ageing -Alzheimer's Association (NIAAA) diagnostic Criteria and 0.5 for MCI and 1 according to CDR criteria.
- Informed consent
- Elderly aged 55 years or above (age, gender and education matched with Dementia subjects)
Show all 14Show fewer
- Persons without MCI/AD (NIAAA Criteria)
- Both genders, only right handed individuals.
- Informed consent Exclusion criteria
- Elderly with MCI or dementia (CDR ≥0.5)
- Patients on medications like antipsychotics, antidepressants and benzodiazepines (some of patients).
- Patient with comorbid clinical conditions like hypothyroidism, hypercalcemia, vitamin B12 deficiency, niacin deficiency, neurosyphilis, normal pressure hydrocephalus or subdural haematoma.
- Persons with other mental disorders like schizophrenia and related disorder, bipolar affective disorder, severe depression, obsessive compulsive disorder, substance dependence and mental retardation.
- History of neurological illness like stroke, epilepsy, head injury with significant loss of consciousness or other chronic neurological/ neurodegenerative conditions.
Who cannot join
- Elderly with more advanced dementia (CDR >1)
- Patients on medications like antipsychotics, antidepressants and benzodiazepines (some of patients).
- Patient with comorbid clinical conditions like hypothyroidism, hypercalcemia, vitamin B12 deficiency, niacin deficiency, neurosyphilis, normal pressure hydrocephalus or subdural haematoma.
- Persons with other mental disorders like schizophrenia and related disorder, bipolar affective disorder, severe depression, obsessive compulsive disorder, substance dependence and mental retardation.
- History of neurological illness like stroke, epilepsy, head injury with significant loss of consciousness or other chronic neurological/ neurodegenerative conditions.
- Elderly Cognitively Healthy Comparison group (n=50)
Trial locations and contacts
2 sites in 1 country.
India2 sites
National Institute of Mental Health and Neurosciences (NIMHANS)
Bengaluru, Karnataka
National Institute of Mental Health and Neurosciences
Bengaluru, Karnataka
About this study
Official title: Brain Connectivity in Mild Cognitive Impairment and Alzheimer's Disease: A Resting and Task-based fMRI-MEG Study Examining Alterations in Functional Connectivity Following Treatment With Transcranial Current Stimulation (tDCS)
The goal of this observational study was to examine the brain functional alterations accompanying cognitive modulatory effect of anodal transcranial Direct Current Stimulation (tDCS) in sample patients with early Alzheimer's Disease (AD), registered under Geriatric Clinic and Services at NIMHANS, and who were initiated on tDCS for cognitive enhancement. Further, to explore the potential beneficial effect of tDCS, the investigators offered the intervention to the first 40 consenting patients from the amnestic Mild Cognitive Impairment (aMCI) (n=21) and mild AD (n=19) samples. The changes in functional connectivity/activations associated with diminished cognitive functions were examined using functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG), between pre- and post-tDCS intervention. The administration of tDCS followed the standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures.
Read the detailed description
As apriori registration was not done before the initiation of the study and all the participants already underwent tDCS intervention, the investigators are herewith submitting the protocol of the study retrospectively following the completion of the project. This study was conducted at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India, with the approval of the NIMHANS Institutional Ethics Committee.
Study Sample: All consenting participants of both sexes (age range: 55 - 84 years) meeting the inclusion and exclusion criteria (see below), who consecutively attended the outpatient services of the Geriatric Clinic and Services (GCS), NIMHANS from August 2019 to December 2022 with memory complaints were recruited in this study with their signed informed consent. Only right-handed individuals were recruited as assessed using the Edinburgh Handedness Inventory (EHI). Participants were screened to ensure that only those with optimal hearing and visual acuity were recruited. The clinical diagnoses of MCI and mild AD made by clinicians at the GCS at NIMHANS were confirmed using the National Institute on Ageing - Alzheimer's Association (NIA-AA) diagnostic criteria and Clinical Dementia Rating [CDR] (CDR scores of 0.5 for MCI and 1 for mild AD). Participants with CDR scores above 1 were excluded from this study. Other exclusion criteria included concurrent medical conditions like hypothyroidism, hypercalcemia, vitamin B12 deficiency, uncontrolled hypertension and diabetes, neurosyphilis, normal pressure hydrocephalus, subdural hematoma, etc., requiring initiation of medical/surgical interventions and/or titration of medications; pre-existing major psychiatric and neurological illnesses, such as schizophrenia spectrum disorders, bipolar affective disorder, major depressive disorder, obsessive-compulsive disorder, substance dependence, intellectual disability disorder, Parkinson's disease and related disorders, stroke, epilepsy, and other chronic neurological/neurodegenerative disorders, and significant head injury; and current usage of antipsychotics, antidepressants, and benzodiazepines. Forty patients (19 MCI and 21 mild AD) consented to participate in the study and completed the tDCS intervention protocol, which comprised daily 20-minute tDCS sessions for 10 days. All participants underwent detailed neuropsychological assessments, resting-state functional magnetic resonance imaging (rsfMRI), task-based functional magnetic resonance imaging (tbfMRI) as well as resting state magnetoencephalography (rsMEG) following tDCS intervention.
Neuropsychological Battery for Elderly (NNB-E): This battery includes tests of episodic memory, executive functions, attention, visuospatial function, and parietal focal signs and required 1.5 hours to administer and score. Assessments were carried out at baseline (pre-tDCS) and after completion of the last tDCS session (post-tDCS). These pre- and post-tDCS assessments were conducted in a way that prevented the same researcher from doing both tests for a particular participant. Additionally, the person conducting the post-tDCS assessment was blind to the results of the pre-assessment. Two different forms were used for the pre-and post-tDCS assessments of a participant to avoid practice effects. Shapiro Wilk test was performed to check the normality distribution of the differences between pre- and post-tDCS scores for each sub-test (n=26) of NNB-E. Accordingly, paired t-tests and Wilcoxon signed rank tests were carried out respectively for normally and non-normally distributed sub-test scores to look for significant effects of tDCS intervention.
Magnetic Resonance Imaging (MRI): The MRIs were acquired on a 3Tesla Philips Ingenia CX (Philips Healthcare, Netherlands) scanner with a 32-channel phased-array head coil. During rs-fMRI acquisition, the participants were instructed to remain physically and mentally relaxed with their eyes open and not focus on anything particular. These functional MR images corresponding to each participant were visually examined for scanner or acquisition-related artifacts. The rs-fMRI data of one participant each from the MCI and mild AD groups showed more than 5% intensity variation in two consecutive volumes indicating poor quality of functional images due to motion artifacts validated using Derivative of root mean square VARiance over voxelS (DVARS). After the exclusion of both pre- and post-rsfMRI scans of these two participants, the data of the remaining 38 participants (n=18 in the MCI group and n=20 in the mild AD group) were further analyzed. The seed for the seed-to-voxel resting state functional connectivity (S2V-rsFC) analysis was set using the Harvard cortical atlas, as the left middle frontal gyrus (lMFG), corresponding to the left DLPFC, the site of the anodal tDCS. The analysis between pre- and post-tDCS intervention was performed using the spherical mask of lMFG as 'seed' and the whole-brain volume for 'voxels'. Two-tailed parametric statistics were implemented to obtain the results using a cluster-level extent threshold (p-FDR corrected) with voxel threshold at p < 0.001 (p-uncorrected) and cluster threshold at p < 0.05 (p-corrected).
A novel episodic memory paradigm, comprising two tasks: an incidental encoding task and an intentional retrieval task, was used for tb-fMRI acquisition. In the incidental encoding task, the participants were instructed on each trial to indicate using a button press whether the presented visual images were of living or non-living objects. In the intentional retrieval task, the instruction for each trial was to indicate using a button press, whether the presented visual images were seen before (memory images, MI) or not seen before (non-memory images, nMI). The optimal number of trials for the incidental encoding task (living objects: 55; non-living objects: 55; fixation cross: 56) and the intentional retrieval task (memory images, MI: 55; non-memory images, nMI: 55; fixation cross: 56) was estimated using the fMRI stimulator to maximize the predictable variance between the three trial classes for each of the two tasks. Only the participants showing more than 60% performance accuracy on both incidental encoding and intentional retrieval were analyzed. Task-based fMRI data pre-processing and analyses of remaining participants with early AD (n=30; MCI=15, mild AD=15) were carried out using FMRI Expert Analysis Tool (FEAT) Version 6.00 of FMRIB Software Library (FSL), implementing high-quality model-based fMRI data analysis. Z (Gaussianised T/F) statistical images were thresholded non-parametrically using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P=0.05.
Magnetoencephalography (MEG): The pre- and post- rsMEG data were acquired using the Elekta Neuromag® TRIUX™ MEG Scanner. Two participants (1 in the MCI sample and 1 in the mild AD sample) opted out of taking part in MEG acquisition, and four participants (3 in the MCI sample and 1 in the mild AD sample) did not participate in post-MEG scans; MEG data of the remaining participants with early AD (n=34; MCI=15, mild AD=19) were further preprocessed. The resting eyes closed MEG recordings were carried out in a sitting position employing the following protocol: sampling rate 2000 Hz, empty room recording=2 minutes, resting-state MEG=15 minutes. EEG data were acquired concurrently to ensure that the participants were alert and relaxed during the recording. Electrocardiogram (ECG), electromyography (EMG), and electrooculogram (EOG) were acquired to remove the heart, muscle, and ocular artifacts, respectively. Quality control (QC) of the MEG data was done using MaxfilterTM (ver 2.2), a built-in software for the ELEKTA/Neuromag system. Suppression of interference due to environmental and periodic artifacts was carried out using the spatiotemporal signal space separation (tSSS) method. Using the Welch method, a power spectrum analysis was performed on 5 minutes of artifact-free MEG recording. Extracted power spectrum density (PSD) values for neural oscillations covered canonical frequency bands [delta (2-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (13-30 Hz), gamma (30-60 Hz) and gamma2 (60-90 Hz)]. A paired T-test was performed between the pre- and post-tDCS values of normalized PSD, correcting for multiple [permutation testing (1000 randomizations), Monte Carlo method] comparisons (FDR-corrected), controlling for time and frequency.
The dependence between the phase of low-frequency oscillations (fP) and the amplitude of high-frequency rhythms (fA) was quantified using phase amplitude coupling (PAC). The coupling strength for each participant was estimated using time-resolved PAC (tPAC), which shows the least relative error. The tPAC was estimated by searching for the fP oscillation with the strongest PAC to fA bursts, over a time window, which slides on the input MEG data. A 10-second epoch length was used for analysis, and since the fP band of interest was between 4-8 Hz, three full cycles of the fP band were chosen to produce a sliding window length of 0.75 seconds. The average comodulograms were extracted using tPAC maps of all the patients with MCI (n=15) and mild AD (n=19) in the left entorhinal cortex which plays a critical role in episodic memory and is vulnerable to early pathophysiology in AD. A paired t-test was performed outside this software using MATLAB® (https://www.mathworks.com) to find out the significant (FDR-corrected p < 0.05) difference in coupling strength between phase of low frequencies (4-8 Hz) and amplitude of high frequencies (30-90 Hz) correcting for multiple comparisons across time and frequency.
- Conditions
- Cognitive Impairment
- Being tested
- anodal transcranial Direct Current Stimulation
- Keywords
- transcranial Direct current Stimulation, Alzheimer Disease, Mild Cognitive Impairment, functional Magnetic Resonance Imaging, Magnetoencephalography
- Medical subject headings
- Cognitive Dysfunction, Alzheimer Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
anodal transcranial Direct Current StimulationDevice
Transcranial direct current stimulation was administered following standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures . None of the participants reported significant adverse effects.
| Study group | Role | What they receive |
|---|---|---|
| early Alzheimer's Disease (AD) | The early AD group comprised of patients with Mild Cognitive Impairment (MCI) and mild Alzheimer's Disease (AD) Receives: Device: anodal transcranial Direct Current Stimulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Magnetic Resonance Imaging
The resting state functional connectivity, incidental encoding and intentional retrieval task based activation were the primary outcome measures of MRI.
Measured: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
Magnetoencephalography
The power of alpha, beta, theta and gamma bandwidths, phase of theta waves and amplitude of gamma band coupling in the left entorhinal cortex were calculated as primary outcome measure of magnetoencephalography
Measured: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
Cognitive assessments
The output of NIMHANS Neuropsychological Battery for Elderly (NNB-E) measuring tests of episodic memory, executive functions, attention, visuospatial function, and parietal focal signs were noted as primary outcome measures of the cognitive assessments used in this study.
Measured: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Mar 2025
- Study start5 Aug 2019
- Primary completion16 Dec 2022
- Study completion16 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (19)Papers the sponsor has linked to this study.
- Other trials for Cognitive ImpairmentStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Institute of Mental Health and Neuro Sciences, India
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, John P John, National Institute of Mental Health and Neuro Sciences, India
- Investigators
- John P John, M.D., Principal investigator, National Institute of Mental Health and Neuro Sciences, India
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06864910
- Sponsor's protocol ID
- DST-CSI/002/208/2018/01156
- Other IDs
- DST/CSRI/2017/249 (G) 28.08.18
- Status last verified
- Mar 2025
- First submitted
- 14 Feb 2025
- Last updated
- 7 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Rodriguez GA, Barrett GM, Duff KE, Hussaini SA. Chemogenetic attenuation of neuronal activity in the entorhinal cortex reduces Abeta and tau pathology in the hippocampus. PLoS Biol. 2020 Aug 21;18(8):e3000851. doi: 10.1371/journal.pbio.3000851. eCollection 2020 Aug.
PubMed 32822389Jacobs J, Kahana MJ, Ekstrom AD, Fried I. Brain oscillations control timing of single-neuron activity in humans. J Neurosci. 2007 Apr 4;27(14):3839-44. doi: 10.1523/JNEUROSCI.4636-06.2007.
PubMed 17409248Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM. Brainstorm: a user-friendly application for MEG/EEG analysis. Comput Intell Neurosci. 2011;2011:879716. doi: 10.1155/2011/879716. Epub 2011 Apr 13.
PubMed 21584256Uusitalo MA, Ilmoniemi RJ. Signal-space projection method for separating MEG or EEG into components. Med Biol Eng Comput. 1997 Mar;35(2):135-40. doi: 10.1007/BF02534144. No abstract available.
PubMed 9136207Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007 Aug 1;37(1):90-101. doi: 10.1016/j.neuroimage.2007.04.042. Epub 2007 May 3.
PubMed 17560126Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R. Movement-related effects in fMRI time-series. Magn Reson Med. 1996 Mar;35(3):346-55. doi: 10.1002/mrm.1910350312.
PubMed 8699946Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage. 2003 Oct;20(2):870-88. doi: 10.1016/S1053-8119(03)00336-7.
PubMed 14568458Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2(3):125-41. doi: 10.1089/brain.2012.0073. Epub 2012 Jul 19.
PubMed 22642651Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012 Feb 1;59(3):2142-54. doi: 10.1016/j.neuroimage.2011.10.018. Epub 2011 Oct 14.
PubMed 22019881Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23 Suppl 1:S208-19. doi: 10.1016/j.neuroimage.2004.07.051.
PubMed 15501092Taulu S, Simola J. Spatiotemporal signal space separation method for rejecting nearby interference in MEG measurements. Phys Med Biol. 2006 Apr 7;51(7):1759-68. doi: 10.1088/0031-9155/51/7/008. Epub 2006 Mar 16.
PubMed 16552102Snodgrass JG, Vanderwart M. A standardized set of 260 pictures: norms for name agreement, image agreement, familiarity, and visual complexity. J Exp Psychol Hum Learn. 1980 Mar;6(2):174-215. doi: 10.1037//0278-7393.6.2.174.
PubMed 7373248Sternberg S. High-speed scanning in human memory. Science. 1966 Aug 5;153(3736):652-4. doi: 10.1126/science.153.3736.652.
PubMed 5939936Gardiner JM. Functional aspects of recollective experience. Mem Cognit. 1988 Jul;16(4):309-13. doi: 10.3758/bf03197041. No abstract available.
PubMed 3210971Parekh P, Bhalerao GV, Rao R, Sreeraj VS, Holla B, Saini J, Venkatasubramanian G, John JP, Jain S; ADBS Consortium. Protocol for magnetic resonance imaging acquisition, quality assurance, and quality check for the Accelerator program for Discovery in Brain disorders using Stem cells. Int J Methods Psychiatr Res. 2021 Sep;30(3):e1871. doi: 10.1002/mpr.1871. Epub 2021 May 7.
PubMed 33960571
Study at a glance
From the registry record, last updated by the sponsor on 7 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Brain Connectivity in Mild Cognitive Impairment and Alzheimer's Disease: A Resting and Task-based fMRI-MEG Study Examining Alterations in Functional Connectivity Following Treatment With Transcranial Current Stimulation (tDCS)
- ClinicalTrials.gov ID
- NCT06864910
- Acronym / sponsor ID
- DST-CSI/002/208/2018/01156
- Conditions
- Cognitive Impairment
- Keywords
- transcranial Direct current Stimulation, Alzheimer Disease, Mild Cognitive Impairment, functional Magnetic Resonance Imaging, Magnetoencephalography
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- National Institute of Mental Health and Neuro Sciences, IndiaUniversity, hospital or other
- Study start
- 5 Aug 2019 (actual)
- Primary completion
- 16 Dec 2022 (actual)
- Study completion
- 16 Dec 2022 (actual)
- First posted
- 7 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study was to examine the brain functional alterations accompanying cognitive modulatory effect of anodal transcranial Direct Current Stimulation (tDCS) in sample patients with early Alzheimer's Disease (AD), registered under Geriatric Clinic and Services at NIMHANS, and who were initiated on tDCS for cognitive enhancement. Further, to explore the potential beneficial effect of tDCS, the investigators offered the intervention to the first 40 consenting patients from the amnestic Mild Cognitive Impairment (aMCI) (n=21) and mild AD (n=19) samples. The changes in functional connectivity/activations associated with diminished cognitive functions were examined using functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG), between pre- and post-tDCS intervention. The administration of tDCS followed the standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures.
Detailed description
As apriori registration was not done before the initiation of the study and all the participants already underwent tDCS intervention, the investigators are herewith submitting the protocol of the study retrospectively following the completion of the project. This study was conducted at the National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India, with the approval of the NIMHANS Institutional Ethics Committee.
Study Sample: All consenting participants of both sexes (age range: 55 - 84 years) meeting the inclusion and exclusion criteria (see below), who consecutively attended the outpatient services of the Geriatric Clinic and Services (GCS), NIMHANS from August 2019 to December 2022 with memory complaints were recruited in this study with their signed informed consent. Only right-handed individuals were recruited as assessed using the Edinburgh Handedness Inventory (EHI). Participants were screened to ensure that only those with optimal hearing and visual acuity were recruited. The clinical diagnoses of MCI and mild AD made by clinicians at the GCS at NIMHANS were confirmed using the National Institute on Ageing - Alzheimer's Association (NIA-AA) diagnostic criteria and Clinical Dementia Rating [CDR] (CDR scores of 0.5 for MCI and 1 for mild AD). Participants with CDR scores above 1 were excluded from this study. Other exclusion criteria included concurrent medical conditions like hypothyroidism, hypercalcemia, vitamin B12 deficiency, uncontrolled hypertension and diabetes, neurosyphilis, normal pressure hydrocephalus, subdural hematoma, etc., requiring initiation of medical/surgical interventions and/or titration of medications; pre-existing major psychiatric and neurological illnesses, such as schizophrenia spectrum disorders, bipolar affective disorder, major depressive disorder, obsessive-compulsive disorder, substance dependence, intellectual disability disorder, Parkinson's disease and related disorders, stroke, epilepsy, and other chronic neurological/neurodegenerative disorders, and significant head injury; and current usage of antipsychotics, antidepressants, and benzodiazepines. Forty patients (19 MCI and 21 mild AD) consented to participate in the study and completed the tDCS intervention protocol, which comprised daily 20-minute tDCS sessions for 10 days. All participants underwent detailed neuropsychological assessments, resting-state functional magnetic resonance imaging (rsfMRI), task-based functional magnetic resonance imaging (tbfMRI) as well as resting state magnetoencephalography (rsMEG) following tDCS intervention.
Neuropsychological Battery for Elderly (NNB-E): This battery includes tests of episodic memory, executive functions, attention, visuospatial function, and parietal focal signs and required 1.5 hours to administer and score. Assessments were carried out at baseline (pre-tDCS) and after completion of the last tDCS session (post-tDCS). These pre- and post-tDCS assessments were conducted in a way that prevented the same researcher from doing both tests for a particular participant. Additionally, the person conducting the post-tDCS assessment was blind to the results of the pre-assessment. Two different forms were used for the pre-and post-tDCS assessments of a participant to avoid practice effects. Shapiro Wilk test was performed to check the normality distribution of the differences between pre- and post-tDCS scores for each sub-test (n=26) of NNB-E. Accordingly, paired t-tests and Wilcoxon signed rank tests were carried out respectively for normally and non-normally distributed sub-test scores to look for significant effects of tDCS intervention.
Magnetic Resonance Imaging (MRI): The MRIs were acquired on a 3Tesla Philips Ingenia CX (Philips Healthcare, Netherlands) scanner with a 32-channel phased-array head coil. During rs-fMRI acquisition, the participants were instructed to remain physically and mentally relaxed with their eyes open and not focus on anything particular. These functional MR images corresponding to each participant were visually examined for scanner or acquisition-related artifacts. The rs-fMRI data of one participant each from the MCI and mild AD groups showed more than 5% intensity variation in two consecutive volumes indicating poor quality of functional images due to motion artifacts validated using Derivative of root mean square VARiance over voxelS (DVARS). After the exclusion of both pre- and post-rsfMRI scans of these two participants, the data of the remaining 38 participants (n=18 in the MCI group and n=20 in the mild AD group) were further analyzed. The seed for the seed-to-voxel resting state functional connectivity (S2V-rsFC) analysis was set using the Harvard cortical atlas, as the left middle frontal gyrus (lMFG), corresponding to the left DLPFC, the site of the anodal tDCS. The analysis between pre- and post-tDCS intervention was performed using the spherical mask of lMFG as 'seed' and the whole-brain volume for 'voxels'. Two-tailed parametric statistics were implemented to obtain the results using a cluster-level extent threshold (p-FDR corrected) with voxel threshold at p < 0.001 (p-uncorrected) and cluster threshold at p < 0.05 (p-corrected).
A novel episodic memory paradigm, comprising two tasks: an incidental encoding task and an intentional retrieval task, was used for tb-fMRI acquisition. In the incidental encoding task, the participants were instructed on each trial to indicate using a button press whether the presented visual images were of living or non-living objects. In the intentional retrieval task, the instruction for each trial was to indicate using a button press, whether the presented visual images were seen before (memory images, MI) or not seen before (non-memory images, nMI). The optimal number of trials for the incidental encoding task (living objects: 55; non-living objects: 55; fixation cross: 56) and the intentional retrieval task (memory images, MI: 55; non-memory images, nMI: 55; fixation cross: 56) was estimated using the fMRI stimulator to maximize the predictable variance between the three trial classes for each of the two tasks. Only the participants showing more than 60% performance accuracy on both incidental encoding and intentional retrieval were analyzed. Task-based fMRI data pre-processing and analyses of remaining participants with early AD (n=30; MCI=15, mild AD=15) were carried out using FMRI Expert Analysis Tool (FEAT) Version 6.00 of FMRIB Software Library (FSL), implementing high-quality model-based fMRI data analysis. Z (Gaussianised T/F) statistical images were thresholded non-parametrically using clusters determined by Z > 2.3 and a corrected cluster significance threshold of P=0.05.
Magnetoencephalography (MEG): The pre- and post- rsMEG data were acquired using the Elekta Neuromag® TRIUX™ MEG Scanner. Two participants (1 in the MCI sample and 1 in the mild AD sample) opted out of taking part in MEG acquisition, and four participants (3 in the MCI sample and 1 in the mild AD sample) did not participate in post-MEG scans; MEG data of the remaining participants with early AD (n=34; MCI=15, mild AD=19) were further preprocessed. The resting eyes closed MEG recordings were carried out in a sitting position employing the following protocol: sampling rate 2000 Hz, empty room recording=2 minutes, resting-state MEG=15 minutes. EEG data were acquired concurrently to ensure that the participants were alert and relaxed during the recording. Electrocardiogram (ECG), electromyography (EMG), and electrooculogram (EOG) were acquired to remove the heart, muscle, and ocular artifacts, respectively. Quality control (QC) of the MEG data was done using MaxfilterTM (ver 2.2), a built-in software for the ELEKTA/Neuromag system. Suppression of interference due to environmental and periodic artifacts was carried out using the spatiotemporal signal space separation (tSSS) method. Using the Welch method, a power spectrum analysis was performed on 5 minutes of artifact-free MEG recording. Extracted power spectrum density (PSD) values for neural oscillations covered canonical frequency bands [delta (2-4 Hz), theta (4-8 Hz), alpha (8-12 Hz), beta (13-30 Hz), gamma (30-60 Hz) and gamma2 (60-90 Hz)]. A paired T-test was performed between the pre- and post-tDCS values of normalized PSD, correcting for multiple [permutation testing (1000 randomizations), Monte Carlo method] comparisons (FDR-corrected), controlling for time and frequency.
The dependence between the phase of low-frequency oscillations (fP) and the amplitude of high-frequency rhythms (fA) was quantified using phase amplitude coupling (PAC). The coupling strength for each participant was estimated using time-resolved PAC (tPAC), which shows the least relative error. The tPAC was estimated by searching for the fP oscillation with the strongest PAC to fA bursts, over a time window, which slides on the input MEG data. A 10-second epoch length was used for analysis, and since the fP band of interest was between 4-8 Hz, three full cycles of the fP band were chosen to produce a sliding window length of 0.75 seconds. The average comodulograms were extracted using tPAC maps of all the patients with MCI (n=15) and mild AD (n=19) in the left entorhinal cortex which plays a critical role in episodic memory and is vulnerable to early pathophysiology in AD. A paired t-test was performed outside this software using MATLAB® (https://www.mathworks.com) to find out the significant (FDR-corrected p < 0.05) difference in coupling strength between phase of low frequencies (4-8 Hz) and amplitude of high frequencies (30-90 Hz) correcting for multiple comparisons across time and frequency.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| early Alzheimer's Disease (AD) | – | Device: anodal transcranial Direct Current StimulationThe early AD group comprised of patients with Mild Cognitive Impairment (MCI) and mild Alzheimer's Disease (AD) |
Who may qualify
- Ages
- 55 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All consecutive patients aged 55 and above attending the Geriatric Clinic and Services at NIMHANS with memory complaints who fulfil the following inclusion and exclusion criteria will be considered for recruitment into the study. Those diagnosed as Minimal Cognitive Impairment or Mild Alzheimer's Dementia by two consultants according to National Institute of Aging and Alzheimer's Association criteria and a Clinical Dementia Rating (CDR) of 0.5 for MCI and 1 for Mild AD would be recruited. Consenting cognitively healthy elderly subjects matched for age and gender to the above with CDR < 0.5 would be parallely recruited.
Key inclusion criteria (14 listed)
- Elderly aged 55 years or above
- Both genders
- Only right handed individuals
- Elderly with a diagnosis of Minimal Cognitive Impairment and Mild AD according to National institute of Ageing -Alzheimer's Association (NIAAA) diagnostic Criteria and 0.5 for MCI and 1 according to CDR criteria.
- Informed consent
Key exclusion criteria (6 listed)
- Elderly with more advanced dementia (CDR >1)
- Patients on medications like antipsychotics, antidepressants and benzodiazepines (some of patients).
- Patient with comorbid clinical conditions like hypothyroidism, hypercalcemia, vitamin B12 deficiency, niacin deficiency, neurosyphilis, normal pressure hydrocephalus or subdural haematoma.
- Persons with other mental disorders like schizophrenia and related disorder, bipolar affective disorder, severe depression, obsessive compulsive disorder, substance dependence and mental retardation.
- History of neurological illness like stroke, epilepsy, head injury with significant loss of consciousness or other chronic neurological/ neurodegenerative conditions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| anodal transcranial Direct Current StimulationTranscranial direct current stimulation was administered following standard procedures using a neuroConn DC-Stimulator Plus device (neuroCare Group GmbH, Munich, Germany) with the anode placed at F3 (left DLPFC) and the cathode over the right supraorbital region (Fp2) using 5x7cm electrodes. The anodal tDCS intervention involved daily sessions (between 10-11 a.m.) for 10 consecutive days, wherein a direct current (DC) of 2 mA was administered for 20 minutes (with additional ramp-up and ramp-down phase of 20 seconds each at the beginning and end of the session respectively), adhering to stringent safety measures . None of the participants reported significant adverse effects. | Device | early Alzheimer's Disease (AD) |
Primary outcome
Magnetic Resonance Imaging
Time frame: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
The resting state functional connectivity, incidental encoding and intentional retrieval task based activation were the primary outcome measures of MRI.
Magnetoencephalography
Time frame: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
The power of alpha, beta, theta and gamma bandwidths, phase of theta waves and amplitude of gamma band coupling in the left entorhinal cortex were calculated as primary outcome measure of magnetoencephalography
Cognitive assessments
Time frame: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days
The output of NIMHANS Neuropsychological Battery for Elderly (NNB-E) measuring tests of episodic memory, executive functions, attention, visuospatial function, and parietal focal signs were noted as primary outcome measures of the cognitive assessments used in this study.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Mar 2025.
- Background: PubMed 32822389Rodriguez GA, Barrett GM, Duff KE, Hussaini SA. Chemogenetic attenuation of neuronal activity in the entorhinal cortex reduces Abeta and tau pathology in the hippocampus. PLoS Biol. 2020 Aug 21;18(8):e3000851. doi: 10.1371/journal.pbio.3000851. eCollection 2020 Aug.
- Background: PubMed 17409248Jacobs J, Kahana MJ, Ekstrom AD, Fried I. Brain oscillations control timing of single-neuron activity in humans. J Neurosci. 2007 Apr 4;27(14):3839-44. doi: 10.1523/JNEUROSCI.4636-06.2007.
- Background: PubMed 21584256Tadel F, Baillet S, Mosher JC, Pantazis D, Leahy RM. Brainstorm: a user-friendly application for MEG/EEG analysis. Comput Intell Neurosci. 2011;2011:879716. doi: 10.1155/2011/879716. Epub 2011 Apr 13.
- Background: PubMed 9136207Uusitalo MA, Ilmoniemi RJ. Signal-space projection method for separating MEG or EEG into components. Med Biol Eng Comput. 1997 Mar;35(2):135-40. doi: 10.1007/BF02534144. No abstract available.
- Background: PubMed 17560126Behzadi Y, Restom K, Liau J, Liu TT. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. Neuroimage. 2007 Aug 1;37(1):90-101. doi: 10.1016/j.neuroimage.2007.04.042. Epub 2007 May 3.
- Background: PubMed 8699946Friston KJ, Williams S, Howard R, Frackowiak RS, Turner R. Movement-related effects in fMRI time-series. Magn Reson Med. 1996 Mar;35(3):346-55. doi: 10.1002/mrm.1910350312.
- Background: PubMed 14568458Andersson JL, Skare S, Ashburner J. How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage. 2003 Oct;20(2):870-88. doi: 10.1016/S1053-8119(03)00336-7.
- Background: PubMed 22642651Whitfield-Gabrieli S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012;2(3):125-41. doi: 10.1089/brain.2012.0073. Epub 2012 Jul 19.
- Background: PubMed 22019881Power JD, Barnes KA, Snyder AZ, Schlaggar BL, Petersen SE. Spurious but systematic correlations in functional connectivity MRI networks arise from subject motion. Neuroimage. 2012 Feb 1;59(3):2142-54. doi: 10.1016/j.neuroimage.2011.10.018. Epub 2011 Oct 14.
- Background: PubMed 15501092Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK, Saunders J, Vickers J, Zhang Y, De Stefano N, Brady JM, Matthews PM. Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage. 2004;23 Suppl 1:S208-19. doi: 10.1016/j.neuroimage.2004.07.051.
- Background: PubMed 16552102Taulu S, Simola J. Spatiotemporal signal space separation method for rejecting nearby interference in MEG measurements. Phys Med Biol. 2006 Apr 7;51(7):1759-68. doi: 10.1088/0031-9155/51/7/008. Epub 2006 Mar 16.
- Background: PubMed 7373248Snodgrass JG, Vanderwart M. A standardized set of 260 pictures: norms for name agreement, image agreement, familiarity, and visual complexity. J Exp Psychol Hum Learn. 1980 Mar;6(2):174-215. doi: 10.1037//0278-7393.6.2.174.
- Individual participant dataSharing planned: No
Related trials for Cognitive Impairment
Recruiting
Telehealth-Adapted Compensatory Training and Intervention for Cognition
MCI, Mild Cognitive Impairment
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Recruiting
Neurobehavioral Changes Following Spaceflight Stressors
Stressor, Individual, Alcohol Impairment
RecruitingPhase 1
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
Alzheimer s Disease, Mild Cognitive Impairment
Recruiting
Treating Insomnia in Mild Cognitive Impairment
Mild Cognitive Impairment (MCI), Insomnia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
John P John, M.D. principal investigator
National Institute of Mental Health and Neuro Sciences, India
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cognitive Impairment, run by National Institute of Mental Health and Neuro Sciences, India at 2 sites in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Magnetic Resonance Imaging (time frame: After the completion of 10 sessions of tDCS (one session per day) spanning across a maximum of 14 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06864910, which also lists 19 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Mar 2025.